218 related articles for article (PubMed ID: 24659264)
21. [Expression and Clinical Significance of MicroRNA-195 in Patients with Diffuse Large B Cell Lymphoma].
Liu RD; Zhuang W; Qi JD; Li CC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):160-164. PubMed ID: 32027270
[TBL] [Abstract][Full Text] [Related]
22. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
23. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
[TBL] [Abstract][Full Text] [Related]
24. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
25. Angiomirs expression profiling in diffuse large B-Cell lymphoma.
Borges NM; do Vale Elias M; Fook-Alves VL; Andrade TA; de Conti ML; Macedo MP; Begnami MD; Campos AH; Etto LY; Bortoluzzo AB; Alves AC; Young KH; Colleoni GW
Oncotarget; 2016 Jan; 7(4):4806-16. PubMed ID: 26683099
[TBL] [Abstract][Full Text] [Related]
26. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Ni H; Wang X; Liu H; Tian F; Song G
Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA Biomarkers in Canine Diffuse Large B-Cell Lymphoma.
Elshafie NO; Nascimento NCD; Lichti NI; Kasinski AL; Childress MO; Santos APD
Vet Pathol; 2021 Jan; 58(1):34-41. PubMed ID: 33287683
[TBL] [Abstract][Full Text] [Related]
28. [Expression of miR-126 in Diffuse Large B-Cell Lymphoma and Its Biological Function].
Qiu C; Zhang QH; Wang GG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1415-1422. PubMed ID: 36208243
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
[TBL] [Abstract][Full Text] [Related]
30. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer.
Park S; Kim J; Eom K; Oh S; Kim S; Kim G; Ahn S; Park KH; Chung D; Lee H
BMC Cancer; 2019 May; 19(1):419. PubMed ID: 31060525
[TBL] [Abstract][Full Text] [Related]
31. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
[TBL] [Abstract][Full Text] [Related]
33. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
34. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
[No Abstract] [Full Text] [Related]
35. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
37. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
38. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
40. Serum miR-21 predicts the prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma.
Ji Q; Jiang T; Su J; Zhang S; Li C; Yang X; Wu X; Yao J; Yuan D; Wang J
Acta Biochim Pol; 2022 Jun; 69(2):379-385. PubMed ID: 35691029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
